Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Jan 4;19:3. doi: 10.1186/s12974-021-02367-w

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2021

Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

PMC Copyright notice

Fig. 6 — Inhibition of the KC/Gro pathway reduces stroke infarct volume and edema but does not reverse the CSF/ventricle shrinkage phenotype in the genetic microglia ablation model. A experimental timeline for stroke experiment. B Representative T2-weighted MRI imaging of vehicle or Repertaxin (Rep) treated mice at 8, 24 and 48 h after stroke. C infarct volume measured by T2-weighted MRI images showed decreased infarct volume in Repertaxin treated mice (n = 9) compared to Vehicle treated mice (n = 6). D Repertaxin treatment also decreased the T2 relaxation time, which is consistent with a reduction in water content. (Two- way ANOVA, treatment p < 0.001 for infarct volume and p < 0.01 for T2 mapping. * or ** and *** indicates p < 0.05, 0.01 and 0.001 for Bonferroni post-hoc tests for repeated measurements). E Experimental timeline for genetic microglia ablation and Repertaxin treatment. F Representative T2-weighted MRI images showing shrinkage of CSF/ventricular spaces in vehicle and Repertaxin treated microglia ablated mouse brain. G MRI image-based quantification of the ventricular volume in control and genetic microglia ablated mice treated with vehicle or Repertaxin using serial coronal sections of T2-weighted MRI after 3 days of Dtx treatment. (n = 3–4 for each group, Mean + SEM, ***p < 0.001, two-way ANOVA with Tukey post-hoc analysis). Data were pooled from two independent experiments showing similar results for both experimental paradigms